A Clinical Study to Assess the Gingivitis Effects of Various Dentifrices

• 0.76% Sodium Monofluorophosphate Dentifrice (Drug): Whole mouth brushing with a toothpaste, twice daily for the duration of the study.
• 1.15% Sodium Monofluorophosphate Dentifrice (Drug): Whole mouth brushing with a toothpaste, twice daily for the duration of the study.
• 0.454% Stannous Fluoride Dentifrice (Drug): Whole mouth brushing with a toothpaste, twice daily for the duration of the study.
• 0.454% Stannous Fluoride Dentifrice (Drug): Whole mouth brushing with a toothpaste, twice daily for the duration of the study.

Primary outcomes

• Löe-Silness Gingivitis Evaluation [3 Months]: Löe-Silness Gingivitis Evaluation is a validated assessment of gingival health looking at inflammation and bleeding based on a 4 point range 0 (normal gingiva) to 3 (severe inflammation).

Secondary outcomes

• Löe-Silness Gingivitis Evaluation [Baseline]: Löe-Silness Gingivitis Evaluation is a validated assessment of gingival health looking at inflammation and bleeding based on a 4 point range 0 (normal gingiva) to 3 (severe inflammation).
• Löe-Silness Gingivitis Evaluation [1 Month]: Löe-Silness Gingivitis Evaluation is a validated assessment of gingival health looking at inflammation and bleeding based on a 4 point range 0 (normal gingiva) to 3 (severe inflammation).

Sex: All, ages: 18 Years to any, accepts healthy volunteers

Inclusion Criteria:

* Be at least 18 years of age;
* Provide written informed consent prior to participation and be given a signed copy of the informed consent form;
* Be in general good health as determined by the Investigator based on a review of the health history/update for participation in the trial;
* Have at least 16 gradable teeth;
* Have mild to moderate gingivitis with a range of 10% to 70% bleeding sites;
* Agree to return for scheduled visits and follow the study procedures;
* Agree to refrain from use of any non-study oral hygiene products for the duration of the study;
* Agree to delay any elective dentistry, including dental prophylaxis, until the completion of the study.

Exclusion Criteria:

* Having taken antibiotic, anti-inflammatory, or anti-coagulant medications within 4 weeks of the Baseline Visit;
* Have any oral conditions that could interfere with study compliance and/or examination procedures, such as widespread caries, soft or hard tissue tumor of the oral cavity, or advanced periodontal disease;
* Removable oral appliances;
* Fixed facial or lingual orthodontic appliances;
* Self-reported pregnancy or lactation;
* Any diseases or condition that might interfere with the safe participation in the study; and
* Inability to undergo study procedures.